Despite these advantages, earlier clinical trials using recombinant TRAIL or soluble TRAIL receptor-agonists for treatment of cancer patients have been halted due to very short blood circulation half-life and poor pharmacokinetic property; indicating that TRAIL monotherapy is not sufficient [16, 18, 19, 21]; and suggesting the importance of TRAIL combination therapy with other potential anticancer agents/modalities to restore TRAIL-apoptotic functionality and to improve overall tumouricidal response [16]. Here, TNFSF10 is linked to cancer.